Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism

• Published in: BMC psychiatry Vol. 10; no. 1; p. 45
• Main Authors: McDonnell, David P, Detke, Holland C, Bergstrom, Richard F, Kothare, Prajakti, Johnson, Jason, Stickelmeyer, Mary, Sanchez-Felix, Manuel V, Sorsaburu, Sebastian, Mitchell, Malcolm I
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 10.06.2010; BioMed Central; BMC
• Subjects: Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Antipsychotic Agents - pharmacokinetics; Benzodiazepines - administration & dosage; Benzodiazepines - adverse effects; Benzodiazepines - pharmacokinetics; Care and treatment; Clinical Trials as Topic - statistics & numerical data; Complications and side effects; Delayed-Action Preparations; Dosage and administration; Drug Overdose - etiology; Drug Overdose - metabolism; Drug-Related Side Effects and Adverse Reactions - diagnosis; Drug-Related Side Effects and Adverse Reactions - metabolism; Drugs; Humans; Injections, Intramuscular; Olanzapine; Overdose; Research article; Schizophrenia; Schizophrenia - drug therapy; Syndrome; Treatment Outcome

Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%...